-+ 0.00%
-+ 0.00%
-+ 0.00%

ENHERTU® PLUS PERTUZUMAB APPROVED IN THE EU AS FIRST NEW REGIMEN IN MORE THAN A DECADE FOR FIRST-LINE TREATMENT OF PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER

Reuters·09/01/2026 06:30:00

Please log in to view news